Published in final edited form as:

J Perinat Med. 2010 ; 38(1): 9–17. doi:10.1515/JPM.2009.134.

LOW CIRCULATING MATERNAL ADIPONECTIN IN PATIENTS WITH PYELONEPHRITIS: ADIPONECTIN AT THE CROSSROADS OF PREGNANCY AND INFECTION

Shali Mazaki-Tovi^{1,2}, Roberto Romero^{1,2,3,*}, Edi Vaisbuch^{1,2}, Tinnakorn Chaiworapongsa^{1,2}, Offer Erez^{1,2}, Pooja Mittal^{1,2}, Sun Kwon Kim¹, Francesca Gotsch¹, Ronald Lamont^{1,2}, Giovanna Ogge¹, Percy Pacora¹, Luis Goncalves¹, Chong Jai Kim¹, Ricardo Gomez⁴, Jimmy Espinoza¹, Sonia S. Hassan^{1,2}, and Juan Pedro Kusanovic^{1,2}

¹Perinatology Research Branch, Intramural Division, NICHD/NIH/DHHS, Hutzel Women's Hospital, Bethesda, MD, and Detroit, MI

²Department of Obstetrics and Gynecology, Wayne State University/Hutzel Women's Hospital, Detroit, MI.

³Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI

⁴Center for Perinatal Diagnosis and Research (CEDIP), Hospital Sotero del Rio, P. Universidad Catolica de Chile, Puente Alto, Chile

Abstract

Objective—An emerging theme in modern biology is that adipose tissue can respond to metabolic stress, and to inflammatory stimuli, by regulating the secretion of a complex network of soluble mediators, termed adipokines. Adiponectin, the most prevalent circulating adipokine in human, has profound insulin-sensitizing and anti-inflammatory properties. Indeed, the notion that adiponectin plays an important role in the interactions between the metabolic and the immune systems has been strongly suggested. Thus, the aim of this study was to determine if pyelonephritis during pregnancy is associated with changes in maternal serum adiponectin concentrations.

Study design—This cross-sectional study included women in the following groups: 1) normal pregnant women (n=200); and 2) pregnant women with pyelonephritis (n=50). Maternal plasma adiponectin concentrations were determined by ELISA. Non-parametric statistics were used for analyses.

Results—1) The median maternal plasma adiponectin concentration was lower in patients with pyelonephritis than in those with a normal pregnancy (p<0.001); 2) among pregnant women with a normal weight, patients with pyelonephritis had a lower median plasma adiponectin concentration than those with a normal pregnancy (p<0.001); 3) similarly, among overweight/obese patients, those with pyelonephritis had a lower median plasma adiponectin concentration than those with a normal pregnancy (p<0.001); and 4) the presence of pyelonephritis was independently associated with maternal plasma adiponectin concentrations after adjustment for maternal age, smoking, gestational age at sampling, and pre-gestational BMI.

Conclusion—1) The findings that acute pyelonephritis in pregnancy is characterized by low maternal plasma concentrations of adiponectin in both lean and overweight/obese patients are novel

*Correspondence: Roberto Romero, MD Perinatology Research Branch, Intramural Division, NICHD/NIH/DHHS, Hutzel Women's Hospital-Box No. 4, 3990 John R, Detroit, MI 48201 USA. Telephone (313) 993-2700, Fax: (313) 993-2694, prbchiefstaff@med.wayne.edu..

and concur with the anti-inflammatory properties of adiponectin; and 2) the results of this study support the notion that adiponectin may play a role in the intricate interface between inflammation and metabolism during pregnancy.

Keywords

adiponectin; adipokines; pregnancy; pyelonephritis; infection; inflammation; acute bacterial infection

Introduction

Adipose tissue has emerged as an active endocrine organ [41,110] that can orchestrate not only a metabolic response to insults, but also an inflammatory response. The mechanisms by which adipose tissue exerts its effects on the immune system have not been completely elucidated. A growing body of evidence suggests that adipocytes modulate resident immune cells functions directly or indirectly, in a paracrine and/or endocrine fashion via the secretion of adipokines [19,90]. The latter is a group of active molecules which are adipocytes-specific or enriched proteins, and includes adiponectin [5,40,99], leptin [126], resistin [35,45,97,108], visfatin [38,101], and others [105,110]. Adipokines have been implicated in a vast array of physiological processes, as well as in inflammation-related pathological conditions such as asthma [31,32], inflammatory bowel disease [112], rheumatoid arthritis [9,98], multiple sclerosis [7] and obesity [5,22,24,46,⁵⁸,⁶⁸,⁷⁰,77-79,88,120]. The metabolic and inflammatory effects of adipokines have been recently corroborated by reports concerning pregnant women, suggesting that adipokines play a role in metabolic adaptations to normal gestation [11,62, 64,66,⁶⁸,70,78,79,106], as well as in inflammation-related [49,59,60,67,68,71,77,113] and other complications of pregnancy [61,63,65,69].

Adiponectin, identified independently by four groups [37,55,76,99], is the adipokine that circulates in the highest concentrations in humans. The range of adiponectin's biological actions includes insulin-sensitizing [8,119], anti-atherogenesis [25,84], and angiogenesis [86, 103]. In addition to its well-established role in glucose metabolism and vasculature protection, adiponectin has anti-inflammatory properties [13,104]. Furthermore, adiponectin is involved in the modulation of both the innate and adaptive limbs of the immune system [82,83,96, 117,118,123,124].

Activation of the innate immune response and suppression of the adaptive immune response are hallmarks of normal human pregnancy.[95] Teleologically, these immunologic alterations aim to promote tolerance to the fetus and protect the mother against infection.[74,95] Nevertheless, pregnant women are more susceptible to infections [15,50,91-93] including those of the lower urinary tract [20,51] and pyelonephritis [27]. Furthermore, pregnant women with an episode of acute pyelonephritis are at risk of developing sepsis and adult respiratory distress syndrome (ARDS) [17,89], though both complications are rare in young non-pregnant individuals. Recently, our group suggested that intra-amniotic adipokines may play a role in the innate immune response against intra-amniotic infection/inflammation (IAI) [49,67,113]. However, despite the compelling evidence supporting the metabolic and inflammatory effects of adiponectin, no data exist about the association between circulating maternal adiponectin and acute systemic bacterial infections. Moreover, the serum/plasma adiponectin concentration in patients with pyelonephritis has not been reported either in pregnant or non-pregnant subjects. Thus, the aim of our study was to determine whether pyelonephritis during pregnancy is associated with changes in maternal plasma adiponectin concentrations.

Materials and methods

Study design and population

A cross-sectional study was conducted by searching our clinical database and bank of biological samples, and included patients in the following groups: (1) normal pregnancy (N=200), and (2) pregnant women with pyelonephritis (N=50). Women were considered to have a normal pregnancy if they met the following criteria: (1) no medical, obstetrical, or surgical complications, (2) absence of labor at the time of venipuncture, and (3) delivery at term (≥ 37 weeks) of a normal healthy infant whose birth weight was between the 10th and 90th percentile for gestational age.[29] Pyelonephritis was diagnosed in the presence of fever (temperature $\geq 38^{\circ}\text{C}$), clinical signs of an upper urinary tract infection (e.g., flank pain, costovertebral angle tenderness), and a positive urine culture for microorganisms.

The body mass index (BMI) was calculated according to the formula: weight (kg)/height (m^2). Normal weight women were defined as those with a BMI of 18.5-24.9 kg/m^2 , according to the definition of the World Health Organization (WHO).[1] The study population was further classified by the pre-gestational BMI into two groups: normal weight and overweight/obese ($\text{BMI} \geq 25 \text{ kg}/\text{m}^2$).

All participating women provided written informed consent prior to enrollment and the collection of blood samples. The collection and use of blood for research purposes was approved by the Institutional Review Boards of both the Sotero del Rio Hospital (Chile) and the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD) (Bethesda, Maryland, USA). Many of these samples have previously been used to study the biology of inflammation, hemostasis, and growth factor concentrations in normal pregnant women and those with pregnancy complications.

Maternal sample collection and determination of adiponectin concentrations

Maternal blood was collected in vials containing ethylenediaminetetra-acetic acid, and centrifuged at 2500 RPM for 10 minutes at 4°C . The plasma obtained was stored at -80°C until analysis. Plasma adiponectin concentrations were determined with the Human Adiponectin ELISA (LINCO Research Inc, St Charles, MO, USA) according to the manufacturer's instructions. The sensitivity of the assay was 0.91 ng/ml, and the intra- and inter-assay coefficients of variation were 4.6% and 6.6%, respectively.

Statistical analysis

Normality of the data was tested using the Kolmogorov-Smirnov tests. Since plasma adiponectin concentrations were not normally distributed, non-parametric test were used for analysis. Comparisons between the two groups were performed using the Mann—Whitney U test for continuous variables and the Chi-square test for categorical variables. Multiple linear regression analysis was used to determine which factors were significantly and independently associated with maternal plasma adiponectin concentration. The following parameters were included in the model: maternal age, smoking, gestational age at sampling, pre-gestational BMI and the presence of pyelonephritis. A p value < 0.05 was considered statistically significant. Analysis was performed with SPSS, version 14 (SPSS Inc., Chicago, IL, USA).

Results

The demographic and clinical characteristics of women with a normal pregnancy and those with pyelonephritis are displayed in Table I. The median birthweight was significantly lower in patients with pyelonephritis than in those with a normal pregnancy. Table II displays the maternal demographic and clinical characteristics of all pregnant women according to BMI

category (normal weight vs. overweight/obese). There were no significant differences in age, nulliparity, smoking status, gestational age at sampling, gestational age at delivery or birthweight between normal weight and overweight/obese women either in the normal pregnancy or pyelonephritis groups.

Adiponectin concentrations in pyelonephritis vs. normal pregnancy

The median maternal plasma adiponectin concentration was lower in patients with pyelonephritis than in those with a normal pregnancy (median: 7,223 ng/mL, interquartile range [IQR] 5,852-8,962 vs. 10,430 ng/mL, IQR 9,262-12,112; $p<0.001$, Figure 1).

Adiponectin concentrations in pyelonephritis: normal weight vs. overweight/obesity

Among patients with pyelonephritis, the median maternal plasma adiponectin concentration was lower in overweight/obese patients than in those with a normal weight (5,164 ng/mL, IQR 4,805-7,997 vs. 7,467 ng/mL, IQR 6,649-9,213; $p=0.02$).

Adiponectin concentrations in normal weight pregnant women: pyelonephritis vs. normal pregnancy

Among pregnant women with a normal weight, those with pyelonephritis had a lower median plasma adiponectin concentration than women with a normal pregnancy (7,467 ng/mL, IQR 6,649-9,213 vs. 10,610 ng/mL, IQR 9,351-12,255; $p<0.001$, Figure 2).

Adiponectin concentrations in overweight/obese pregnant women: pyelonephritis vs. normal pregnancy

Among overweight/obese pregnant women, those with pyelonephritis had a lower median plasma adiponectin concentration than women with a normal pregnancy (5,164 ng/mL, IQR 4,805-7,997 vs. 9,981 ng/mL, IQR 8,801-11,850; $p<0.001$, Figure 3).

Multiple linear regression analysis was employed to examine the relationship between the plasma concentrations of adiponectin and pyelonephritis, while adjusting for maternal age, smoking status, and gestational age at blood sampling. The final regression model suggested that the presence of pyelonephritis and pre-gestational BMI were independently associated with low maternal plasma adiponectin concentrations ($p<0.001$ and $p=0.03$, respectively).

Discussion

Principal findings of the study

1) The median maternal plasma adiponectin concentration was significantly lower in patients with pyelonephritis than in those with a normal pregnancy; 2) among pregnant women with a normal weight, those with pyelonephritis had a significantly lower median plasma adiponectin concentration than women with a normal pregnancy; 3) similarly, among pregnant women with overweight/obesity, those with pyelonephritis had a significantly lower median plasma adiponectin concentration than women with a normal pregnancy; and 4) the presence of pyelonephritis was independently associated with maternal plasma adiponectin concentrations after adjustment for maternal age, smoking, gestational age at sampling, and pre-gestational BMI.

Pregnancy and pyelonephritis — an ominous combination

Pyelonephritis complicates 1–2% of pregnancies [34,72], and it is one of the most common indications for antepartum hospitalization [6,23]. Pyelonephritis occurs approximately 70% of the time during the second and third trimesters, 25% in the postpartum period and only 4% of cases present during the first trimester [27,72]. The clinical course of most patients is favorable

and resolution of the fever is expected in 95% of the cases within 72 hours of adequate antimicrobial treatment [72]. Nonetheless, pregnant women with pyelonephritis are at risk of developing sepsis [10,53,102] and ARDS [3,12,14,16,²¹,33,34,52,89]. Moreover, pyelonephritis is the most common cause of septic shock during pregnancy [53,102] and the most frequent indication for admission to obstetric intensive care units [125].

Adiponectin and immunity: bridging the gap between inflammation and metabolism?

Adiponectin, the most abundant gene (*AMP1*) product of adipose tissue [37,55,76,99], has a wide range of biological activities. Adiponectin has been implicated in the pathophysiology of insulin resistance [8,36,73,115,119], atherosclerosis [81,83,85], hypertension [39,42], and dyslipidemia [18,57]. In addition to its well-characterized metabolic effects, several lines of evidence suggest that adiponectin is an important mediator of inflammatory responses: 1) adiponectin suppresses macrophage production of pro-inflammatory cytokines, such as TNF- α [124], (IFN- γ) [117] and IL-6 [100]; 2) exposure of macrophages to adiponectin results in inhibition of their phagocytic activity in response to stimulation with lipopolysaccharide (LPS) [124]; 3) adiponectin inhibits activation of the nuclear transcription factor NF- κ B in endothelial cells [85]; and 4) in knockout mice, gene deletion of adiponectin results in higher TNF- α mRNA expression in adipose tissue, as well as higher circulating TNF- α concentrations than “adiponectin-sufficient” mice (wild type) [56]. Taken together, this unique combination of biological effects makes adiponectin a plausible candidate to orchestrate the functional interphase between metabolism and inflammation.

Pyelonephritis is characterized by low maternal circulating adiponectin

The findings reported herein characterize pyelonephritis during pregnancy as a condition associated with low maternal circulating adiponectin concentrations. Moreover, lower maternal concentrations were detected in pyelonephritis in patients who were either of normal weight or overweight/obese. These findings are novel. Reports concerning circulating adiponectin concentrations in the presence of infectious disorders in non-pregnant patients are scarce and no data exists concerning maternal circulating concentrations of this adipokine in any infectious disease. Furthermore, no information regarding plasma/serum adiponectin concentrations in the presence of pyelonephritis either in non-pregnant or in pregnant patients is available.

The findings reported herein contrast with two studies that examined the effect of experimental endotoxemia on human circulating adiponectin concentrations. Keller et al. [43] reported no change in adiponectin plasma concentrations in endotoxin-injected subjects (n=23). Similarly, Anderson et al. [4] found no significant difference in plasma adiponectin before and after intravenous endotoxin injection (n=20). Differences in study design may contribute to explain the apparent inconsistency between the studies. Specifically, the studies of Keller et al. [43] and Anderson et al. [4] included only 4 and 10 women, respectively, and pregnancy was an exclusion criterion. In addition, the study population was younger than the one included in the present study, and almost all participants had a normal BMI. Finally, the effect on adiponectin concentrations was determined in both studies no more than 24 hours after exposure to the endotoxin.

Why is pyelonephritis associated with low maternal adiponectin concentrations?

Several possibilities can account for the low maternal circulating adiponectin concentrations and pyelonephritis:

1. Regulatory mechanism to increase insulin resistance—An episode of acute infection imposes metabolic challenges to the mother. Indeed, acute infection/inflammation is associated with hypermetabolism, enhanced energy expenditure, and insulin resistance [26,

28,109,111]. The acute nature of pyelonephritis necessitates prompt metabolic adaptations to ensure constant flow of nutrients to both the fetus and the mother. The low maternal plasma adiponectin concentrations reported herein in patients with pyelonephritis favor a state of insulin resistance which enhances the availability of glucose to the fetus. Thus, it is conceivable that the low concentrations of circulating adiponectin are part of the metabolic adaptations aimed at ensuring the flux of glucose to the fetus.

2. Counter-inflammatory response—Low concentrations of circulating adiponectin have been associated with the presence of systemic inflammation. Indeed, patients with inflammatory bowel disease [114], atopic dermatitis and eczema [75], asthma and overweight/obesity [2,5,37,44,78,88] have lower circulating adiponectin concentrations than normal controls. The results of the present study support the association between pro-inflammatory conditions and low adiponectin concentrations and extend these data by showing that low circulating concentrations of this adipokine characterize acute bacterial infection during pregnancy.

3. Binding to circulating lipopolysaccharide (LPS)—Bacteremia is a common finding in pregnant women with pyelonephritis since 15 to 45% of patients have a positive blood culture [30,48,54,80,107]. Furthermore, pyelonephritis-related sepsis is the most frequent indication for admission to obstetric intensive care units [125], as well as the most common cause of septic shock during pregnancy [53,102]. Bacterial pathogens that are isolated from blood cultures rarely differ from those that are found in the corresponding urine culture and include predominantly Gram-negative bacteria that possess endotoxin (e.g. *Escherichia coli* and *Klebsiella pneumoniae*). A recent report demonstrated that human adiponectin directly binds LPS derived from several different bacteria including *E. coli*. [87] It was proposed that adiponectin infiltrates into inflammation sites, and may act as a scavenging anti-inflammatory agent through its interaction with LPS [87]. It is tempting to suggest that the low circulating maternal adiponectin concentration is the consequence of adiponectin binding to the LPS and the infecting bacteria.

4. Increased urine secretion—While there are conflicting data as to whether chronic renal diseases are associated with higher [127] or lower [122] circulating adiponectin concentrations, than in normal subjects, several studies have demonstrated an increase in urine adiponectin in the presence of renal dysfunction [47,94,121]. Transient renal insufficiency with a decrease in creatinine clearance of at least 50% or more is reported in more than 25% of patients with pyelonephritis [72,116]. Thus, a possible explanation for the lower maternal plasma adiponectin could be increased secretion of this adipokine in the urine. Further studies are needed in order to establish the relationship between maternal serum and urine adiponectin in pyelonephritis.

In conclusion, acute pyelonephritis in pregnancy is characterized by low maternal plasma concentrations of adiponectin. The present study represents the first work to describe an *in-vivo* association between acute bacterial infection and altered circulating adiponectin concentrations. The unique combination of the biologic properties of adiponectin and its important role in energy homeostasis and inflammatory processes supports a role for this adipokine in the complex linkage between metabolism and infection. As pregnancy is characterized by physiologic adaptations involving metabolic processes and immunologic systems, the regulation of these two systems is particularly pertinent during normal gestation and complications of pregnancy. Taken together, the findings reported herein support a role for adiponectin in the intricate interface between pregnancy, inflammation and metabolism.

Acknowledgments

This research was supported (in part) by the Perinatology Research Branch, Division of Intramural Research, *Eunice Kennedy Shriver* National Institute of Child Health and Human Development, NIH, DHHS.

Reference List

1. Diet, nutrition and the prevention of chronic diseases. World Health Organ Tech.Rep.Ser 2003;916:i–149. backcover. [PubMed: 12768890]
2. Abbasi F, Chu JW, Lamendola C, McLaughlin T, Hayden J, Reaven GM, et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. *Diabetes* 2004;53:585–590. [PubMed: 14988241]
3. Amstey MS. Frequency of adult respiratory distress syndrome in pregnant women who have pyelonephritis. *Clin.Infect.Dis* 1992;14:1260–1261. [PubMed: 1530741]
4. Anderson PD, Mehta NN, Wolfe ML, Hinkle CC, Pruscino L, Comiskey LL, et al. Innate immunity modulates adipokines in humans. *J Clin.Endocrinol.Metab* 2007;92:2272–2279. [PubMed: 17374708]
5. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem.Biophys.Res.Commun* 1999;257:79–83. [PubMed: 10092513]
6. Bacak SJ, Callaghan WM, Dietz PM, Crouse C. Pregnancy-associated hospitalizations in the United States, 1999–2000. *Am.J.Obstet.Gynecol* 2005;192:592–597. [PubMed: 15696008]
7. Batocchi AP, Rotondi M, Caggiula M, Frisullo G, Odoardi F, Nociti V, et al. Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. *J.Neuroimmunol* 2003;139:150–154. [PubMed: 12799033]
8. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. *Nat.Med* 2001;7:947–953. [PubMed: 11479628]
9. Bernotiene E, Palmer G, Talabot-Ayer D, Szalay-Quinodoz I, Aubert ML, Gabay C. Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice. *Arthritis Res.Ther* 2004;6:R256–R263. [PubMed: 15142272]
10. Bubeck RW. Acute pyelonephritis during pregnancy with anuria, septicemia and thrombocytopenia. *Del.Med J* 1968;40:143–147. [PubMed: 5655841]
11. Catalano PM, Hoegh M, Minium J, Huston-Presley L, Bernard S, Kalhan S, et al. Adiponectin in human pregnancy: implications for regulation of glucose and lipid metabolism. *Diabetologia* 2006;49:1677–1685. [PubMed: 16752186]
12. Catanzarite VA, Willms D. Adult respiratory distress syndrome in pregnancy: report of three cases and review of the literature. *Obstet.Gynecol.Surv* 1997;52:381–392. [PubMed: 9178312]
13. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? *Diabetes Care* 2003;26:2442–2450. [PubMed: 12882876]
14. Cole DE, Taylor TL, McCullough DM, Shoff CT, Derdak S. Acute respiratory distress syndrome in pregnancy. *Crit Care Med* 2005;33:S269–S278. [PubMed: 16215347]
15. Cox S, Posner SF, McPheeters M, Jamieson DJ, Kourtis AP, Meikle S. Hospitalizations with respiratory illness among pregnant women during influenza season. *Obstet.Gynecol* 2006;107:1315–1322. [PubMed: 16738158]
16. Cunningham FG, Leveno KJ, Hankins GD, Whalley PJ. Respiratory insufficiency associated with pyelonephritis during pregnancy. *Obstet.Gynecol* 1984;63:121–125. [PubMed: 6537862]
17. Cunningham FG, Morris GB, Mickal A. Acute pyelonephritis of pregnancy: A clinical review. *Obstet Gynecol* 1973;42:112–117. [PubMed: 4720190]
18. Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. *N.Engl.J.Med* 2005;353:2121–2134. [PubMed: 16291982]
19. Desruisseaux MS, Nagajyothi, Trujillo ME, Tanowitz HB, Scherer PE. Adipocyte, adipose tissue, and infectious disease. *Infect.Immun* 2007;75:1066–1078. [PubMed: 17118983]
20. Dixon HG, Brant HA. The significance of bacteriuria in pregnancy. *Lancet* 1967;1:19–20. [PubMed: 4163738]

21. Elkington KW, Greb LC. Adult respiratory distress syndrome as a complication of acute pyelonephritis during pregnancy: case report and discussion. *Obstet.Gynecol* 1986;67:18S–20S. [PubMed: 3945462]
22. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. *JAMA* 2003;289:1799–1804. [PubMed: 12684358]
23. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality. *Ann.Epidemiol* 2003;13:144–150. [PubMed: 12559674]
24. Frayn KN. Obesity and metabolic disease: is adipose tissue the culprit? *Proc.Nutr.Soc* 2005;64:7–13. [PubMed: 15877917]
25. Funahashi T, Nakamura T, Shimomura I, Maeda K, Kuriyama H, Takahashi M, et al. Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity. *Intern.Med* 1999;38:202–206. [PubMed: 10225688]
26. Garza C. Effect of infection on energy requirements of infants and children. *Public Health Nutr* 2005;8:1187–1190. [PubMed: 16277828]
27. Gilstrap LC III, Cunningham FG, Whalley PJ. Acute pyelonephritis in pregnancy: an anterospective study. *Obstet.Gynecol* 1981;57:409–413. [PubMed: 7243084]
28. Goldstein SA, Elwyn DH. The effects of injury and sepsis on fuel utilization. *Annu.Rev.Nutr* 1989;9:445–473. [PubMed: 2669881]
29. Gonzalez RP, Gomez RM, Castro RS, Nien JK, Merino PO, Etchegaray AB, et al. A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000. *Rev.Med.Chil* 2004;132:1155–1165. [PubMed: 15631202]
30. Gotsch F, Romero R, Espinoza J, Kusanovic JP, Mazaki-Tovi S, Erez O, et al. Maternal serum concentrations of the chemokine CXCL10/IP-10 are elevated in acute pyelonephritis during pregnancy. *J.Matern.Fetal Neonatal Med* 2007;20:735–744. [PubMed: 17763275]
31. Guler N, Kirerleri E, Ones U, Tamay Z, Salmayenli N, Darendeliler F. Leptin: does it have any role in childhood asthma? *J.Allergy Clin.Immunol* 2004;114:254–259. [PubMed: 15316499]
32. Gurkan F, Atamer Y, Ece A, Kocyigit Y, Tuzun H, Mete N. Serum leptin levels in asthmatic children treated with an inhaled corticosteroid. *Ann.Allergy Asthma Immunol* 2004;93:277–280. [PubMed: 15478389]
33. Gurman G, Schlaeffer F, Kopernic G. Adult respiratory distress syndrome as a complication of acute pyelonephritis during pregnancy. *Eur.J.Obstet.Gynecol.Reprod.Biol* 1990;36:75–80. [PubMed: 2194868]
34. Hill JB, Sheffield JS, McIntire DD, Wendel GD Jr. Acute pyelonephritis in pregnancy. *Obstet.Gynecol* 2005;105:18–23. [PubMed: 15625136]
35. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W, et al. FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. *EMBO J* 2000;19:4046–4055. [PubMed: 10921885]
36. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler.Thromb.Vasc.Biol* 2000;20:1595–1599. [PubMed: 10845877]
37. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. *J.Biol.Chem* 1996;271:10697–10703. [PubMed: 8631877]
38. Hug C, Lodish HF. Medicine. Visfatin: a new adipokine. *Science* 2005;307:366–367. [PubMed: 15604359]
39. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor for hypertension. *Hypertension* 2004;43:1318–1323. [PubMed: 15123570]
40. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. *Endocr.Rev* 2005;26:439–451. [PubMed: 15897298]
41. Kahn BB, Flier JS. Obesity and insulin resistance. *J.Clin.Invest* 2000;106:473–481. [PubMed: 10953022]

42. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. *Diabetes Care* 2002;25:971–976. [PubMed: 12032101]
43. Keller P, Moller K, Krabbe KS, Pedersen BK. Circulating adiponectin levels during human endotoxaemia. *Clin.Exp.Immunol* 2003;134:107–110. [PubMed: 12974762]
44. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. *Diabetes* 2003;52:1779–1785. [PubMed: 12829646]
45. Kim KH, Lee K, Moon YS, Sul HS. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. *J.Biol.Chem* 2001;276:11252–11256. [PubMed: 11278254]
46. Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. *Obes.Rev* 2007;8:21–34. [PubMed: 17212793]
47. Koshimura J, Fujita H, Narita T, Shimotomai T, Hosoba M, Yoshioka N, et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. *Biochem.Biophys.Res.Comm* 2004;316:165–169. [PubMed: 15003525]
48. Kusanovic JP, Romero R, Esinoza J, Gotsch F, Edwin S, Chaiwaropongsa T, et al. Maternal serum soluble CD30 is increased in pregnancies complicated with acute pyelonephritis. *J.Matern.Fetal Neonatal Med* 2007;20:803–811. [PubMed: 17853184]
49. Kusanovic JP, Romero R, Mazaki-Tovi S, Chaiwaropongsa T, Mittal P, Gotsch F, et al. Resistin in amniotic fluid and its association with intra-amniotic infection and inflammation. *J Matern Fetal Neonatal Med* 2008;21:902–916. [PubMed: 19065463]
50. Laibl VR, Sheffield JS. Influenza and pneumonia in pregnancy. *Clin.Perinatol* 2005;32:727–738. [PubMed: 16085029]
51. Little PJ. The incidence of urinary infection in 5000 pregnant women. *Lancet* 1966;2:925–928. [PubMed: 4162367]
52. Mabie WC, Barton JR, Sibai BM. Adult respiratory distress syndrome in pregnancy. *Am.J.Obstet.Gynecol* 1992;167:950–957. [PubMed: 1415431]
53. Mabie WC, Barton JR, Sibai BM. Septic shock in pregnancy. *Obstetrics and Gynecology* 1997;90:553–561. [PubMed: 9380315]
54. MacMillan MC, Grimes DA. The limited usefulness of urine and blood cultures in treating pyelonephritis in pregnancy. *Obstet.Gynecol* 1991;78:745–748. [PubMed: 1923190]
55. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). *Biochem.Biophys.Res.Comm* 1996;221:286–289. [PubMed: 8619847]
56. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. *Nat.Med* 2002;8:731–737. [PubMed: 12068289]
57. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. *J.Clin.Endocrinol.Metab* 2002;87:2764–2769. [PubMed: 12050247]
58. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Mittal P, et al. Adiponectin in amniotic fluid in normal pregnancy, spontaneous labor at term, and preterm labor: A novel association with subclinical intrauterine infection/inflammation. *J. Matern. Fetal Neonatal Med.* 2009 In Press.
59. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Chaiwaropongsa T, Mittal P, et al. Maternal Plasma Visfatin in Preterm Labor. *J Matern.Fetal Neonatal Med.* 2009 DOI 10.1080/14767050902994655.
60. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Dysregulation of maternal serum adiponectin in preterm labor. *J.Matern.Fetal Neonatal Med.* 2009 DOI 10.1515/JPM.2009.101.
61. Mazaki-Tovi S, Romero R, Vaisbuch E, Erez O, Mittal P, Chaiwaropongsa T, et al. Maternal Serum Adiponectin Multimers in Gestational Diabetes. *Journal Of Perinatal Medicine.* 2009
62. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Efraty Y, Schiff E, et al. Determining the source of fetal adiponectin. *J.Reprod.Med* 2007;52:774–778. [PubMed: 17939592]
63. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Schiff E, Sivan E. Cord blood adiponectin in large-for-gestational age newborns. *Am.J.Obstet.Gynecol* 2005;193:1238–1242. [PubMed: 16157144]

64. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Wiser A, Schiff E, et al. Maternal serum adiponectin levels during human pregnancy. *J.Perinatol* 2007;27:77–81. [PubMed: 17262038]
65. Mazaki-Tovi S, Kanety H, Pariente C, Hemi R, Yinon Y, Wiser A, et al. Adiponectin and leptin concentrations in dichorionic twins with discordant and concordant growth. *J Clin.Endocrinol.Metab* 2009;94:892–898. [PubMed: 19066299]
66. Mazaki-Tovi S, Kanety H, Sivan E. Adiponectin and human pregnancy. *Curr.Diab.Rep* 2005;5:278–281. [PubMed: 16033679]
67. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Mittal P, et al. Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition. *J Perinat.Med* 2008;36:485–496. [PubMed: 18598235]
68. Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Gotsch F, et al. Adiponectin multimers in maternal plasma. *J.Matern.Fetal Neonatal Med* 2008;21:796–815. [PubMed: 19031276]
69. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Visfatin in human pregnancy: maternal gestational diabetes vis-a-vis neonatal birthweight. *J Perinat.Med.* 2008
70. Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, et al. Maternal visfatin concentration in normal pregnancy. *J Perinat.Med* 2009;37:206–217. [PubMed: 19284295]
71. Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Gotsch F, et al. Maternal serum adiponectin multimers in preeclampsia. *J Perinat.Med* 2009;37:349–363. [PubMed: 19348608]
72. Mittal P, Wing DA. Urinary tract infections in pregnancy. *Clin.Perinatol* 2005;32:749–764. [PubMed: 16085031]
73. Modan-Moses D, Stein D, Pariente C, Yaroslavsky A, Ram A, Faigin M, et al. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. *J.Clin.Endocrinol.Metab* 2007;92:1843–1847. [PubMed: 17327386]
74. Naccasha N, Gervasi MT, Chaiworapongsa T, Berman S, Yoon BH, Maymon E, et al. Phenotypic and metabolic characteristics of monocytes and granulocytes in normal pregnancy and maternal infection. *Am.J.Obstet.Gynecol* 2001;185:1118–1123. [PubMed: 11717644]
75. Nagel G, Koenig W, Rapp K, Wabitsch M, Zoellner I, Weiland SK. Associations of adipokines with asthma, rhinoconjunctivitis, and eczema in German schoolchildren. *Pediatr.Allergy Immunol* 2009;20:81–88. [PubMed: 18331416]
76. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, Tomita M. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. *J.Biochem.(Tokyo)* 1996;120:803–812. [PubMed: 8947845]
77. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Adiponectin in severe preeclampsia. *J.Perinat.Med* 2007;35:503–512. [PubMed: 17919115]
78. Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, et al. Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. *J.Perinat.Med* 2007;35:522–531. [PubMed: 17919116]
79. Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, et al. Resistin: a hormone which induces insulin resistance is increased in normal pregnancy. *J.Perinat.Med* 2007;35:513–521. [PubMed: 17919114]
80. Nien JK, Romero R, Hoppensteadt D, Erez O, Espinoza J, Soto E, et al. Pyelonephritis during pregnancy: a cause for an acquired deficiency of protein Z. *J Matern Fetal Neonatal Med* 2008;21:629–637. [PubMed: 18828054]
81. Okamoto Y, Arita Y, Nishida M, Muraguchi M, Ouchi N, Takahashi M, et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. *Horm.Metab Res* 2000;32:47–50. [PubMed: 10741683]
82. Okamoto Y, Folco EJ, Minami M, Wara AK, Feinberg MW, Sukhova GK, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherosclerosis. *Circ.Res* 2008;102:218–225. [PubMed: 17991878]
83. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation* 1999;100:2473–2476. [PubMed: 10604883]

84. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. *Circulation* 2001;103:1057–1063. [PubMed: 11222466]
85. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. *Circulation* 2000;102:1296–1301. [PubMed: 10982546]
86. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. *J.Biol.Chem* 2004;279:1304–1309. [PubMed: 14557259]
87. Peake PW, Shen Y, Campbell LV, Charlesworth JA. Human adiponectin binds to bacterial lipopolysaccharide. *Biochem.Biophys.Res.Commun* 2006;341:108–115. [PubMed: 16431217]
88. Pinhas-Hamiel O, Singer S, Pilpel N, Koren I, Boiko V, Hemi R, et al. Adiponectin levels in adolescent girls with polycystic ovary syndrome. *Clin.Endocrinol.(Oxf)*. 2009 DOI: 10.111/j.1365-2265.2009.03604.
89. Pruett K, Faro S. Pyelonephritis associated with respiratory distress. *Obstet.Gynecol* 1987;69:444–446. [PubMed: 3543771]
90. Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. *Endocrinology* 2003;144:3765–3773. [PubMed: 12933646]
91. Rodrigues J, Niederman MS. Pneumonia complicating pregnancy. *Clin.Chest Med* 1992;13:679–691. [PubMed: 1478027]
92. Romero R, Kusanovic JP, Espinoza J, Gotsch F, Nhan-Chang CL, Erez O, et al. What is amniotic fluid 'sludge'? *Ultrasound Obstet.Gynecol* 2007;30:793–798. [PubMed: 17899615]
93. Romero R, Schaudinn C, Kusanovic JP, Gorur A, Gotsch F, Webster P, et al. Detection of a microbial biofilm in intraamniotic infection. *Am.J Obstet.Gynecol* 2008;198:135, e1–5. [PubMed: 18166328]
94. Rovin BH, Song H, Hebert LA, Nadasdy T, Nadasdy G, Birmingham DJ, et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. *Kidney Int* 2005;68:1825–1833. [PubMed: 16164660]
95. Sacks G, Sargent I, Redman C. An innate view of human pregnancy. *Immunol.Today* 1999;20:114–118. [PubMed: 10203701]
96. Saijo S, Nagata K, Nakano Y, Tobe T, Kobayashi Y. Inhibition by adiponectin of IL-8 production by human macrophages upon coculturing with late apoptotic cells. *Biochem.Biophys.Res.Commun* 2005;334:1180–1183. [PubMed: 16039610]
97. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. *Diabetes* 2001;50:2199–2202. [PubMed: 11574398]
98. Schaffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Scholmerich J, et al. Adipocytokines in synovial fluid. *JAMA* 2003;290:1709–1710. [PubMed: 14519703]
99. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. *J.Biol.Chem* 1995;270:26746–26749. [PubMed: 7592907]
100. Schober F, Neumeier M, Weigert J, Wurm S, Wanninger J, Schaffler A, et al. Low molecular weight adiponectin negatively correlates with the waist circumference and monocytic IL-6 release. *Biochem.Biophys.Res.Commun* 2007;361:968–973. [PubMed: 17678873]
101. Sethi JK, Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? *Trends Mol.Med* 2005;11:344–347. [PubMed: 16005682]
102. Sheffield JS. Sepsis and septic shock in pregnancy. *Crit Care Clin* 2004;20:651–660. [PubMed: 15388194]
103. Shibata R, Ouchi N, Kihara S, Sato K, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. *J.Biol.Chem* 2004;279:28670–28674. [PubMed: 15123726]
104. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. *J.Clin.Endocrinol.Metab* 2003;88:3236–3240. [PubMed: 12843170]
105. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. *J.Clin.Invest* 2006;116:1793–1801. [PubMed: 16823477]

106. Sivan E, Mazaki-Tovi S, Pariente C, Efraty Y, Schiff E, Hemi R, et al. Adiponectin in human cord blood: relation to fetal birth weight and gender. *J.Clin.Endocrinol.Metab* 2003;88:5656–5660. [PubMed: 14671149]
107. Soto E, Richani K, Romero R, Espinoza J, Chaiworapongsa T, Nien JK, et al. Increased concentration of the complement split product C5a in acute pyelonephritis during pregnancy. *J.Matern.Fetal Neonatal Med* 2005;17:247–252. [PubMed: 16147833]
108. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. *Nature* 2001;409:307–312. [PubMed: 11201732]
109. Tappy L, Chioloro R. Substrate utilization in sepsis and multiple organ failure. *Crit Care Med* 2007;35:S531–S534. [PubMed: 17713404]
110. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat.Rev.Immunol* 2006;6:772–783. [PubMed: 16998510]
111. Trager K, DeBacker D, Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. *Curr.Opin.Crit Care* 2003;9:271–278. [PubMed: 12883281]
112. Tuzun A, Uygun A, Yesilova Z, Ozel AM, Erdil A, Yaman H, et al. Leptin levels in the acute stage of ulcerative colitis. *J.Gastroenterol.Hepatol* 2004;19:429–432. [PubMed: 15012781]
113. Vaisbuch E, Mazaki-Tovi S, Kusanovic JP, Erez O, Than GN, Kim SK, et al. Retinol Binding Protein 4: An Adipokine Associated with Intra-amniotic Infection / Inflammation. *J Matern Fetal Neonatal Med*. 2009 In Press.
114. Valentini L, Wirth EK, Schweizer U, Hengstermann S, Schaper L, Koernicke T, et al. Circulating adipokines and the protective effects of hyperinsulinemia in inflammatory bowel disease. *Nutrition* 2009;25:172–181. [PubMed: 18849144]
115. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J.Clin.Endocrinol.Metab* 2001;86:1930–1935. [PubMed: 11344187]
116. Whalley PJ, Cunningham FG, Martin FG. Transient renal dysfunction associated with acute pyelonephritis of pregnancy. *Obstet.Gynecol* 1975;46:174–177. [PubMed: 1097976]
117. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. *Biochem.Biophys.Res.Commun* 2004;323:630–635. [PubMed: 15369797]
118. Yamaguchi N, Argueta JG, Masuhiro Y, Kagishita M, Nonaka K, Saito T, et al. Adiponectin inhibits Toll-like receptor family-induced signaling. *FEBS Lett* 2005;579:6821–6826. [PubMed: 16325814]
119. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. *Nat.Med* 2001;7:941–946. [PubMed: 11479627]
120. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. *J.Clin.Endocrinol.Metab* 2001;86:3815–3819. [PubMed: 11502817]
121. Yaturu S, Reddy RD, Rains J, Jain SK. Plasma and urine levels of resistin and adiponectin in chronic kidney disease. *Cytokine* 2007;37:1–5. [PubMed: 17383891]
122. Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Kir T, et al. Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients. *Clin.Nephrol* 2005;64:12–19. [PubMed: 16047640]
123. Yokota T, Meka CS, Kouro T, Medina KL, Igarashi H, Takahashi M, et al. Adiponectin, a fat cell product, influences the earliest lymphocyte precursors in bone marrow cultures by activation of the cyclooxygenase-prostaglandin pathway in stromal cells. *J.Immunol* 2003;171:5091–5099. [PubMed: 14607907]
124. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. *Blood* 2000;96:1723–1732. [PubMed: 10961870]
125. Zeeman GG, Wendel GD Jr. Cunningham FG. A blueprint for obstetric critical care. *Am.J.Obstet.Gynecol* 2003;188:532–536. [PubMed: 12592267]

126. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. *Nature* 1994;372:425–432. [PubMed: 7984236]
127. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. *J.Am.Soc.Nephrol* 2002;13:134–141. [PubMed: 11752030]

Figure 1. Comparison of the median maternal plasma adiponectin concentration between women with normal pregnancies and patients with pyelonephritis

The median maternal plasma adiponectin concentration was lower in patients with pyelonephritis than in those with a normal pregnancy (7,223 ng/mL, IQR 5,852-8,962 vs. 10,430 ng/mL, IQR 9,262-12,112; $p < 0.001$).

Figure 2. Comparison of the median maternal plasma adiponectin concentration in normal weight pregnant women with normal pregnancy and patients with pyelonephritis

Among pregnant women with a normal weight, those with pyelonephritis had a lower median plasma adiponectin concentration than women with a normal pregnancy (7,467 ng/mL, IQR 6,649-9,213 vs. 10,610 ng/mL, IQR 9,351-12,255; $p < 0.001$).

Figure 3. Comparison of the median maternal plasma adiponectin concentration in overweight/obese pregnant women with normal pregnancy and patients with pyelonephritis

Among overweight/obese pregnant women, those with pyelonephritis had a lower median plasma adiponectin concentration than women with a normal pregnancy (5,164 ng/mL, IQR 4,805-7,997 vs. 9,981 ng/mL, IQR 8,801-11,850; $p < 0.001$).

Table 1

Clinical and demographic characteristics of the study population

	Normal Pregnancy (n=200)	Pyelonephritis (n=50)	p
Maternal age (years)	26 (21-31)	27 (21-30)	0.9
Nulliparity	78 (36%)	23 (46%)	0.4
Smoking	14 (7%)	7 (14%)	0.1
Pre-gestational BMI (kg/m²)	23.1 (21.1-24.9)	22.7 (20.2-25.6)	0.5
BMI at blood sampling (kg/m²)	26.9 (24.8-29.6)	25.4 (23.7-27.9)	0.09
GA at blood sampling (weeks)	31.0 (25.3-38.2)	28.9 (21.6-33.2)	0.2
GA at delivery (weeks)	39.8 (38.6-40.3)	39.2 (38.2-40.1)	0.09
Birth weight (g)	3400 (3172-3670)	3140 (2990-3505)	<0.01

Values are expressed as median (interquartile range) or numbers (%); GA- Gestational age; BMI — Body Mass Index

Table 2
Clinical and demographic characteristics of the study population according to body mass index

	Normal Pregnancy		Pyelonephritis	
	Normal Weight (n=149)	Overweight/Obese (n=51)	Normal Weight (n=35)	Overweight/Obese (n=15)
Maternal age (years)	25 (20-31)	27 (22-31)	24 (21-31)	28 (21-29)
Nulliparity	62 (42%)	16 (31%)	17 (48%)	6 (40%)
Smoking	12 (8%)	2 (4%)	5 (14%)	2 (13%)
Pre-gestational BMI (kg/m ²)	22.3 (20.8-23.4)	26.9 (26.0-30.0)	21.6 (19.9-23.1)	27.4 (26.0-28.4)
BMI at blood sampling (kg/m ²)	25.8 (24.0-27.7)	31.5 (29.3-34.0)	24.7 (22.3-25.6)	28.0 (27.4-31.0)
GA at blood sampling (weeks)	29.1 (24.7-33.7)	29.2 (25.8-38.4)	28.8 (21.4-34.4)	28.2 (21.5-32.1)
GA at delivery (weeks)	40.0 (38.6-40.0)	39.7 (39.0-40.4)	39.1 (38.3-39.1)	40.0 (37.3-40.3)
Birth weight (g)	3410 (3210-3780)	3440 (3155-3670)	3140 (3020-3430)	3160 (2640-3780)

Values are expressed as median (interquartile range) or numbers (%); GA- Gestational age; BMI — Body Mass Index